Prevention of lysosomal storage in Tay-Sachs mice treated with N-butyldeoxynojirimycin.
basic_science · Level V
Where this comes from
- Record sourced from PubMed, PMID 9103204.
- No licence information is recorded for this record.
- Because redistribution is not established, this page shows the abstract only. Follow the links below for the full text.
Abstract
The glycosphingolipid (GSL) lysosomal storage diseases result from the inheritance of defects in the genes encoding the enzymes required for catabolism of GSLs within lysosomes. A strategy for the treatment of these diseases, based on an inhibitor of GSL biosynthesis N-butyldeoxynojirimycin, was evaluated in a mouse model of Tay-Sachs disease. When Tay-Sachs mice were treated with N-butyldeoxynojirimycin, the accumulation of GM2 in the brain was prevented, with the number of storage neurons and the quantity of ganglioside stored per cell markedly reduced. Thus, limiting the biosynthesis of the substrate (GM2) for the defective enzyme (beta-hexosaminidase A) prevents GSL accumulation and the neuropathology associated with its lysosomal storage.
Medical subject headings
- 1-Deoxynojirimycin
- Brain
- Enzyme Inhibitors
- G(M2) Ganglioside
- Lysosomes
- Tay-Sachs Disease